Navigation Links
Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
Date:3/30/2011

PRINCETON, N.J., March 30, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously.

"We are encouraged by the early efficacy and safety data being generated with our nucleotide analogs, PSI-7977 and PSI-938," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "The ATOMIC trial is designed to explore 12 and 24 week durations of PSI-7977. The potency, high barrier to resistance, and consistent antiviral activity across genotypes provided the data to support an interferon free dosing period in this trial, as well as enabling us to enroll multiple genotypes in this trial."  

About the Phase 2b ATOMIC Trial

This Phase 2b trial is planned to enroll approximately 300 patients with chronic HCV genotype 1 who have not been treated previously. The primary endpoint of the trial will be the safety and tolerability of PSI-7977 in combination with peginterferon and ribavirin over 12 or 24 weeks. The trial will be conducted in the U.S. Patients will be randomized (1:2:3) into the following arms:

  • PSI-7977 400mg QD with peginterferon and ribavirin for 12 weeks;
  • PSI-7977 400mg QD with peginterferon and ribavirin for 24 weeks;
  • PSI-7977 400mg QD with peginterferon and ribavirin for 12 weeks, followed by either PSI-7977 400mg QD monotherapy for 12 weeks or PSI-7977 400mg QD plus ribavirin for 12 weeks.

HCV GT1 patients will be stratified by IL28B status and baseline HCV RNA to ensure balance across cohorts. An additional 25 treatment-naïve patients w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Webcast an Investor Event From the EASL Meeting
2. Pharmasset to Present at Three Upcoming Investor Conferences
3. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
4. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
5. Pharmasset Announces Exercise of Underwriters Overallotment Option
6. Pharmasset Prices Public Offering of Common Stock
7. Pharmasset Announces Proposed Public Offering of Common Stock
8. Pharmasset Reports Positive Results from its HCV Clinical Programs
9. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
11. Pharmasset to Webcast an Investor Event from the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... FREMONT, Calif. , July 7, 2015  The ... and Velos, Inc. have entered into a seven year ... research nationally throughout South Korea and ... signing was accompanied by a two day joint workshop between ... Korea.  National Cancer Center President Dr. Lee ...
(Date:7/7/2015)... , Kalifornien, 7. Juli 2015 /PRNewswire/ ... Medizintechnikunternehmen, das sich der Entwicklung innovativer Geräte ... heute den Zugang von R. Michael ... Herr Kleine verfügt über eine ... Medizintechnik und Gesundheitsfürsorge. Er hat verschiedene globale ...
(Date:7/7/2015)... Md. , July 7, 2015 ... (CRO) focusing in Oncology, Vaccines, and General Medicine ... the final locked database to Heron Therapeutics, Inc. ... 3 receptor antagonist product candidate SUSTOL® (granisetron ... regimen with the IV NK 1 receptor ...
Breaking Medicine Technology:National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 3Sequent Medical beruft Mike Kleine in den Aufsichtsrat 2Sequent Medical beruft Mike Kleine in den Aufsichtsrat 3Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2
... ALTO, Calif., Jan. 10, 2012 Varian Medical Systems (NYSE: ... a new radiotherapy treatment planning tool designed to work with ... the amount of time needed for planning advanced treatments. ... clinician must take the patient,s anatomical images and identify and ...
... Agreement allows development for potential treatment of chronic constipation ... SHPGY ), the global specialty biopharmaceutical company, announced today ... market Resolor ® (prucalopride) in the United States ... of the agreement have not been disclosed. ...
Cached Medicine Technology:Varian Medical Systems Receives FDA 510(k) Clearance for Software that Speeds Up Radiotherapy Treatment Planning 2Shire Acquires US Rights to Resolor(R) (prucalopride) 2Shire Acquires US Rights to Resolor(R) (prucalopride) 3Shire Acquires US Rights to Resolor(R) (prucalopride) 4
(Date:7/7/2015)... ... July 08, 2015 , ... The OR Business Management Conference ... business managers increase efficiency, reduce supply chain costs, optimize throughput, and improve patient ... Phoenix Glendale, February 21-24, 2016. The agenda has been announced and includes four ...
(Date:7/7/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in pharmacy. NAPW ... members and over 200 operating Local Chapters. , ā€œIā€™m pleased to recognize Alyssa with ...
(Date:7/7/2015)... ... July 08, 2015 , ... LAGOS, Nigeria ā€“ In ... crafts a poignant, stirring tale about a young woman who deals with abuse, alienation ... Taking place in a poor, superstitious village in Eastern Nigeria and in ...
(Date:7/7/2015)... Angeles, CA (PRWEB) , ... July 07, 2015 ... ... engineer of patented products, announces the IV Tube Holder, a medical invention that ... largest medical device market in the world which will be worth $133 billion ...
(Date:7/7/2015)... ... ... reputable source of authentic tickets for the CONCACAF Gold Cup Group A matches ... Massachusetts. , The second round of matches being held from Group A of the 2015 ... be held on Friday, July 10th and will feature Honduras vs. Panama and the United ...
Breaking Medicine News(10 mins):Health News:Agenda, Pre-Conference Workshop, and More Announced for OR Business Management Conference 2Health News:Agenda, Pre-Conference Workshop, and More Announced for OR Business Management Conference 3Health News:National Association of Professional Women Inducts Dr. Alyssa Greedy, Pharm. D., Pharmacy Manager at Walgreens, Into its VIP Woman of the Year Circle 2Health News:Uju Amanambu crafts poignant tale depicting woes of mental illness 2Health News:Uju Amanambu crafts poignant tale depicting woes of mental illness 3Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 2Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 3Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 4Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 5Health News:CONCACAF Group A Tickets: USA vs. Haiti & Honduras vs. Panama at Gillette Stadium: Ticket Down Slashes CONCACAF Gold Cup Group A Tickets in Foxborough 2
... more clinical preventive services, dedicate funding source to public ... 11 Partnership for Prevention today unveiled health ... and health promotion efforts to tackle the chronic diseases ... , Under these proposals, federally ...
... Inc. (Nasdaq: PTIE ) has received a Complete Response ... New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of ... the NDA is not approved in its present form. ... non-clinical data will be required to support the approval of REMOXY. ...
... touted as the "cure" for health care, but a new ... that implementation of technology and related devices is not a ... safety of patient care. , , ... to understanding when a technology may (or may not) be ...
... Dental Management,Services, Inc. (Nasdaq: BDMS ), operators ... The Company,s board of directors,has declared a quarterly ... stock.,The dividend is payable January 9, 2009, to shareholders ... Birner Dental Management Services, Inc. acquires, develops, ...
... agonists may cause asthma problems and death, agency officials ... of four asthma medications will be weighed by a U.S. ... hearings end Thursday. , The controversy over these drugs has ... recently calling for banning the use of these drugs for ...
... PRA International, a leading,Clinical Research Organization, announces ... Mexico. With years of long-standing South American ... The region,s existing base of clinical,sites with expertise ... to PRA,s therapeutic focus. The expansion is ...
Cached Medicine News:Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 2Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 3Health News:FDA Panel Mulls Safety of Asthma Meds 2Health News:FDA Panel Mulls Safety of Asthma Meds 3Health News:PRA International Expands Operations in Mexico 2
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
Medicine Products: